key: cord-0020593-7bhi0et3
authors: Imagawa, Toshifumi; Ito, Masahiko; Matsuda, Mami; Nakashima, Kenji; Tokunaga, Yuhei; Ohta, Isao; Li, Tian-Cheng; Suzuki, Ryosuke; Suzuki, Tetsuro
title: Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate
date: 2021-09-02
journal: Sci Rep
DOI: 10.1038/s41598-021-97038-4
sha: 7875bc5d1dd681989aacba1a754dee354722f316
doc_id: 20593
cord_uid: 7bhi0et3

The global incidence of dengue, which is caused by dengue virus (DENV) infection, has grown dramatically in recent decades and secondary infection with heterologous serotype of the virus may cause severe symptoms. Efficacious dengue vaccines should be able to provide long-lasting immunity against all four DENV serotypes simultaneously. In this study, we constructed a novel vaccine platform based on tetravalent dengue virus-like particles (DENV-LPs) in which envelope (E) protein carried a FLAG tag sequence at the position located not only in the exterior loop on the protruding domain but outside of dimerization interface of the protein. We demonstrated an effective strategy to produce the DENV-LPs by transient transfection with expression plasmids for pre-membrane and E proteins of DENV-1 to DENV-4 in mammalian cells and to concentrate and purify them with one-step affinity chromatography. Characteristic features of VLPs such as particle size, shape and density were comparable to flavivirus-like particles reported. The neutralizing activity against all four DENV serotypes was successfully induced by immunization with the purified tetravalent VLPs in mice. Simple, one-step purification systems for VLP vaccine platforms using epitope-tagging strategy should be advantageous for vaccine development not only for dengue but for emerging pandemics in the future.

www.nature.com/scientificreports/ The E protein is the major target for antibody-mediated neutralization and thus the focus of vaccine design 7 . Due to the possible phenomenon of ADE in which infection with heterogenous serotype induces severe dengue pathogenesis, the challenge for development of dengue vaccine has been to generate a tetravalent vaccine that induces protective immunity against DENV-1, DENV-2, DENV-3, and DENV-4, simultaneously 8 .

CYD-TDV, a tetravalent live attenuated with a yellow fever backbone is the first dengue vaccine to be licensed in late 2015 9 . It was shown that the rate of severe dengue infection after immunization with CYD-TDV potentially increased in dengue antibody negative children compared to dengue antibody positive children 10 . The first licensed vaccine led to controversy, thus no dengue vaccine is in widespread use to date.

Virus-like particle (VLP) has been developed as one of new candidates of dengue vaccine in several studies. Since VLPs have structural and physicochemical features comparable to infectious particles, it is expected that immunogenicity is comparable to mature virion and it is not needed to consider occurrence of the vaccine derived strain. In fact, immunization with Dengue VLP successfully induced anti-DENV antibody 11, 12 and cytotoxic T cell response 11, 13 , whereas it appears that the ADE of DENV infection was not induced by the VLP vaccination at least in mouse models 14, 15 . Dengue VLPs have been produced by several protein expression systems using such as mammalian cells 11, 12 , yeast Pichia pastoris 14 , Escherichia coli 16 , also silkworm transfected with recombinant baculovirus genome 17 . VLPs produced by recombinant expression systems have been purified through stepwise processes such as clarification, precipitation, ultrafiltration and chromatography.

In this study, we identified an optimal insertion site for FLAG tag sequence in DENV E protein for extracellularly production of DENV-LPs derived from four serotypes and established a rapid one-step purification system for DENV-LPs using the FLAG affinity purification technology. Further we demonstrated that tetravalent vaccination with purified DENV-LPs elicited neutralizing activities against all four serotypes of DENV simultaneously in mice.

To identify an optimal insertion site for foreign epitope in DENV E protein, we designed three prME expression plasmids carrying the FLAG epitope tag sequence either between amino acid (aa) residues 77 and 78 (FL-77), 223 and 224 (FL-223), or 273 and 274 (FL-273), located within the loop regions in DENV-1 E protein (Fig. 1a, b) , based on the three-dimensional structure and the former study on Japanese encephalitis virus (JEV) sub-viral particles containing FLAG tag or hepatitis C virus-neutralizing epitope 18 . Since these three insertion sites located within domain II of the E protein are predicted to be located in the exterior loop on the protruding domain of the protein and spatially distant from domain III which is regarded as an important epitope for neutralizing activity 19 , an impact by the foreign epitope insertion on the viral antigenic response appears limited.

HEK293T cells transiently transfected with each prME construct were assessed for expression of processed E protein by western blotting. Among tested, the DENV-1 E protein with FLAG insertion at aa 273/274 (FL-273) was most efficiently expressed and secreted into the culture supernatants (Fig. 1c) . As shown in the blotting with anti-glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) antibody as a loading control, it is noted that samples from FL-273 were diluted more than others before analyses (see legend of Fig. 1c) . Further, the identified position, which is not required for multimerization of E protein and is localized on the surface of the virus particle, is predicted to be spatially conserved among all serotypes of DENV (Fig. 2a) . Thus, to generate VLPs of DENV-2, DENV-3 and DENV-4 with FLAG tag, three prME expression plasmids carrying FLAG tag at the corresponding position 273/274 in E protein of DENV-2, DENV-4 and the position 271/272 in E protein of DENV-3, respectively, were constructed and their expression, together with DENV-1, was compared. Under the same transfection condition, the steady state level of E protein from DENV-1 and DENV-3 in cells was higher compared to that from DENV-2 and DENV-4 ( Fig. 2b, left) . In contract, the secreted protein level from DENV-2 was the highest, followed in order by DENV-4, DENV-3 and DENV-1 (Fig. 2b, right) . Nonetheless, the results showed that a certain amount of FLAG-tagged E protein secreted was detectable in the cultures expressing either prME construct from DENV-1 to DENV-4.

As references, expression from original, non-tagged version of prME constructs was also tested by transient transfection as above (Fig. 2c) . Although the E protein levels in cells and culture supernatants derived from DENV-2 and DENV-3 were to some extent higher than those from DENV-1 and DENV-4, their difference among DENV-1, DENV-2, DENV-3 and DENV-4 appeared limited compared in the case of FLAG tagged version. The results indicate that, while three-dimensional structures of E protein are largely similar among all four serotypes of DENV, an influence of the foreign epitope insertion on the protein expression and secretion is potentially observed dependent on the viral serotypes or isolates/clones.

DENV-2 VLP presenting FLAG tag in E protein was expressed in HEK293T cells and purified from culture supernatants by utilizing magnetic beads conjugated with an anti-FLAG (DYKDDDDK) antibody. The eluted fraction was subjected to SDS-PAGE and analyzed by Coomassie brilliant blue (CBB) staining, indicating a major nearly 55 kDa FLAG-DENV-2 E protein (Fig. 3a) . The density of the purified DENV-LP was around 1.17-1.20 g/mL, which is similar to that of dengue virion reported 20, 21 , as determined by sucrose density gradient centrifugation (Fig. 3b) . VLPs with FLAG insertion derived from DENV-1, -3 and -4 were also purified in the same way (Fig. 3c) . The yield of DENV-LPs after purification, as determined by comparing bands between serial dilutions of BSA and purified VLPs in CBB staining, were up to about 250, 1500, 750, and 500 mg/l (data not shown), respectively, for DENV-1, DENV-2, DENV-3 and DENV-4. Transmission electron microscopy of DENV-LPs displayed semi-smooth spherical particles with irregular sizes with diameters of 30-50 nm (Fig. 3d) , which are similar to those previously reported 12 www.nature.com/scientificreports/ Neutralizing activity of sera from mice immunized with tetravalent DENV-LPs. To evaluate the neutralizing antibody response in mice induced by tetravalent DENV-LPs purified as described above, BALB/c mice were immunized with 40 µg of tetravalent DENV-LP mixture, which consists of 10 µg DENV-1 to DENV-4 VLPs individually, two times followed by the third injection with a half dose of DENV-1 to DENV-4 VLPs at 3-week intervals. Neutralizing activities of the immunized sera were assessed using four kinds of single-round infectious particles (SRIPs) possessing structural proteins derived from DENV-1 to DENV-4 individually. As shown in Fig. 4a , sera from immunized mice significantly reduced SRIP infection by all DENV serotypes. In particular, the 50% inhibitory dilution titer of the immunized sera against DENV-1, DENV-2 and DENV-3 were 1:160 or more dilution. A human serum positive with Zika virus IgG almost completely blocked the infection of any DENV SRIPs even at 1:640 dilution (Fig. 4b) . These results thus demonstrated that our tetravalent dengue vaccine platform based on DENV-LPs with FLAG insertion elicited neutralizing antibody response against all serotypes concurrently.

Dengue is now the most frequent arboviral disease and represents an increasingly significant cause of morbidity in the world. One of the most difficulties to develop an effective dengue vaccine is the interaction among the four serotypes of DENV, leading to immunopathology of severe dengue. Although infection with one of the four serotypes potentially induces lasting protection against homotypic re-infection, secondary heterotypic infection is known to be associated with an increased risk of severe disease. Thus, vaccine development has been focusing on the generation of a tetravalent vaccine that enables to provide long-term protection against all four DENV serotypes. www.nature.com/scientificreports/

In this study, we demonstrated an effective strategy to produce DENV VLPs containing the FLAG tag and to concentrate and purify them with one-step chromatography. The main reason for choosing FLAG tag was that we have found that VLP formation can be maintained when introduced into the E protein of JEV, a closely related virus to DENV 18 and that techniques for highly specific one-step purification of fusion proteins by affinity pull-down using anti-FLAG agarose beads have been established. Characteristic features of purified VLP such as particle size, shape and density were basically comparable to flavivirus like particles reported previously 12, 22, 23 . The tetravalent dengue vaccine candidate, which consisted of purified VLPs derived from DENV-1 to DENV-4, was found to induce neutralizing responses against all serotypes of DENV. Further investigation should be focused on determining an optimal condition for induction of the protection activity against infection with DENV-1 to DENV-4.

Typical purification process of extracellularly produced flaviviral VLPs is made up of a variety of steps including centrifugation or depth filtration for cell debris removal and fractionation by density gradient www.nature.com/scientificreports/ centrifugation in combination with size-exclusion chromatography and ion exchange chromatography as labscale processes 11, 12, [24] [25] [26] . However, in general the ultracentrifugation step is not applicable to industrial-scale processes due to its limitation in scalability and variability. As affinity purification technology, immobilized metal ion adsorption chromatography with poly-histidine tag is a versatile and conventional method to purify the recombinant protein 25 but it is known that problems such as low purity of the target proteins eluted from the column or unexpected elution during sample loading/washing frequently arise compared to the methods with specific antigen-antibody affinity purification. Compared to non-enveloped VLPs such as human papillomavirus and hepatitis E virus, enveloped VLPs appear to pose a challenge due to their lower stability. The FLAG tag pull-down technique might be advantageous for purification of enveloped VLPs, since VLPs presenting FLAG can be eluted in mild pH condition with the peptide solution. www.nature.com/scientificreports/ In the first part of this study, we selected the aa residues 273/274 in the E protein as an optimal insertion site of FLAG tag for efficient production and secretion of DENV-1 derived VLP among three sites, aa 77/78, 223/224 and 273/274. Further, this VLP design carrying the FLAG tag was found to be applicable to DENV-2, DENV-3 and DENV-4 and allowed to develop a set-up for purification of DENV-LPs of all serotypes by affinity pull-down using anti-FLAG agarose beads. In designing where to insert the FLAG tag into the DENV-1 E protein, we referred to the results of a previous study on JEV, in which 11 sites for insertion of FLAG tag in the loop region of JEV E protein were tested for VLP production and three constructs were capable of production and secretion of JEV-LP 18 . Crystallographic studies have shown that the E protein consists of three structurally distinct domains: a central domain (domain I), a dimerization domain (domain II), and an immunoglobulinlike C terminal domain (domain III) 6 . The three sites used here were chosen from the viewpoints of predicted location; (1) in the exterior loop on the protruding domain of the E protein, (2) apart from the key determinant of neutralizing antibody (domain III) and (3) outside of dimerization interface of the protein. While located in domain II, formation of the E protein dimer is presumably not perturbed by a certain foreign epitope inserted at any of these sites, considering conformational states of the E protein. It may be likely that the FLAG peptide sequence insertion either at aa 77/78 or 223/224, rather than at aa 273/274, in the E protein resulted in impairing stability, dimer-dimer interaction and/or transportation during maturation of DENV-LP. A comprehensive structure-function analysis has shown that several residues relatively near aa 273 and 274 in the C terminal region of domain II such as aa 258 (methionine), 259 (histidine), and 265 (alanine) are critical for an efficient expression of DENV E protein and budding of the particles assembled 27 . In contrast to aa 273 and 274, it is supposed that these three critical residues are exposed on the underside of E protein and contact with the M protein residues. The efficiency of VLP production varied depending on DENV types/clones. The amino acid sequence homology between the four E proteins used in this study ranges from 40.5 (DENV-3 versus DENV-4) to 72.3% (DENV-1 versus DENV-3). Although the three-dimensional structures of the four E proteins are basically similar, there are some differences in the amino acid sequences, which may lead to differences in the stability of the E proteins and the efficiency of VLP assembly and/or secretion.

The on-going COVID-19 pandemic has indicated the importance of shortening timelines to develop vaccines effective for prophylaxis of emerging-and/or reemerging infectious diseases with global pandemic risk. Establishment of rapid one-step purification systems for VLP vaccine platforms, using tagging strategy, should be advantageous for vaccine development not only for dengue but for emerging pandemics. Our strategy would bear the potential to serve as a template for vaccine platform and be applied to development of VLP vaccines for other viruses, with minor adaptations.

Plasmids. Expression plasmids for pre-membrane (prM) and envelope (E) protein of DENV-1 inserting FLAG tag sequence (DYKDDDDK) either at aa residues 77 and 78, 223 and 224, or 273 and 274, were generated as follows. DENV-1 prME expressing plasmid, pCAG_D1YG1_prME, was prepared by amplifying cDNA encoding prME of DENV-1 (D1/Hu/Saitama/NIID100/2014) 28 and being cloned into pCAGGS. Then the linear FLAG tag inserted pCAG_D1YG1_prME was amplified by inverse PCR with the FLAG tag inserted PCR primer pair binding each position. The amplified liner FLAG tag containing plasmid DNA was self-ligated using In Fusion HD Cloning Kit (TaKaRa, Shiga, Japan), yielding pDENV1-FL77/78, -FL223/224, and -FL273/274.

prM/E expression plasmids for DENV-2, DENV-3 and DENV-4 with FLAG-tag insertion in E protein at aa 273 and 274 for pcD2ME CO (DENV-2), pcD4ME Th (DENV-4), and at aa 271 and 272 of pcD3ME SG (DENV-3) 28 which have two amino acids deletion before the insertion position, were similarly constructed and used as templates and cloning vectors, yielding pDENV2-FL273/274, pDENV4-FL273/274, and pDENV3-FL271/272, respectively.

Homology modeling of DENV E protein structure.. The 3D structures of E protein derived from DENV-1 to DENV-4 were created from aa sequences used in this study by using SWISS-MODEL server (https:// swiss model. expasy. org) 29 . Crystal structures of E protein of DENV-1 (Protein Data Bank [PDB] ID: 4GT0), DENV-2 (PDB ID: 7BUB), DENV-3 (PDB ID: 1UZG) and DENV-4 (PDB ID: 3UAJ) were used as templates to build homology models. These structures were visualized and colored with UCSF Chimera 1.14 software (https:// www. rbvi. ucsf. edu/ chime ra) 30 .

Expression and purification of DENV-LPs.. Human embryonic kidney HEK293T cells, which were maintained in D-MEM with 10% of FBS, were transfected with prM/E expression plasmids using Lipofectamin LTX Reagent (Life technologies, Carlsbad, USA) or linear polyethylenimine, MW25000 (Thermo Fisher Scientific). To purify DENV-LPs, culture supernatants of the transfected cells were harvested 2-3 days post-transfection and then clarified by centrifugation. DYKDDDDK tag magnetic beads (Wako, Osaka, Japan) was added to the resulting supernatants and were rotated overnight at 4 ℃. Captured protein was released competitively using DYKDDDDK peptide (Wako, Osaka, Japan) with rotating for 1-2 h at 4 ℃. Purified VLP solutions were stored at − 80 ℃ before use.

Protein electrophoresis and western blotting. Protein expression and purification was confirmed by SDS-polyacrylamide gel electrophoresis (PAGE) with 12.5% or 17% gel, followed by staining with Coomassie brilliant blue staining solution, EzStain Aqua (ATTO, Tokyo, Japan). For Western blotting, proteins after SDS-PAGE were transferred on PVDF membrane, followed by blocking with Block Ace (KAC Co., Ltd., Kyoto, Japan). Anti-flavi group antigen antibody (D1-4G2-4-15, Merck, Darmstadt, Germany), anti-DYKDDDDK tag antibody (Wako, Osaka, Japan) and anti-GAPDH antibody (Santa Cruz Biotechnology, Dallas, USA) were used Transmission electron microscopy (TEM). TEM analysis was performed as described previously 31 . In brief, VLP solutions were concentrated with Amicon ultra 0.5 centrifugal filter 10 k (Merck, Darmstadt, Germany) and exchange solvent to ultra pure water, followed by placing onto a formvar-coated copper grid and negatively stained with 2% uranyl acetate solution. The samples were observed by using a JEM-1400 plus electron microscope (JEOL Ltd., Tokyo, Japan) operating at an acceleration voltage of 100 kV. Digital images were captured by using a CCD camera.

Immunization of mice. Female BALB/c mice (9 weeks of age) were purchased from SLC Japan and used for VLP immunization. Inoculums were prepared by equivalent volume of tetravalent VLP mixture containing purified VLPs derived from DENV-1 to DENV-4 and Titer Max Gold (TiterMax USA Inc., GA, USA) adjuvant were mixed. Similarly, saline was mixed with the adjuvant as a negative control. Mice (VLP group; n = 4, control group; n = 5) were immunized three times at 3-week intervals. The VLP mixture consisting of 10 µg of each VLP (DENV-1, -2, -3 and -4) was intraperitoneally inoculated at the first and second shots, and the mixture containing 5 µg of each VLP was inoculated at the third challenge. Serum samples were collected at 3 weeks after the third immunization. Mice used were euthanized by exsanguination under deep anesthesia using midazolam, medetomidine and butorphanol tartrate. 

(SRIPs) assay 28 . Four kinds of SRIPs carrying M and E proteins derived from DENV-1, -2, -3, and -4 individually were prepared as described 28 . HEK293T cells were co-transfected with three plasmids; a DENV-1-derived subgenomic replicon plasmid containing nanoluciferase gene, a DENV-1 capsid-expression plasmid, and a plasmid exprerssing prME either derived from DENV-1, -2, -3 or -4. The culture media were harvested after 3 days of transfection and used as SRIPs carrying each type of DENV envelope. Serially-diluted immunized sera were mixed with each SRIP (approximately 100 infectious unit/well) at a 1:1 ratio, followed by adding to monolayers of African green monkey kidney Vero cells. After 3 days of incubation, luciferase activity in cells was determined using the Nano-Glo Luciferase Assay System (Promega, WI, USA). The neutralization titer of immunized serum was evaluated by relative inhibition rate of SRIPs infection compared to the mean inhibition rate of control serum in each dilution. Zika virus NS1 IgG-positive human serum samples were purchased from TRINA BIO-REACTIVES AG (Switzerland) and used as a positive control for neutralization.

Statistical comparison between two study groups in the neutralization test was analyzed by Welch's test using R software version 3.0.0 32 . P values less than 0.05 were determined as significantly difference. www.nature.com/scientificreports/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.

The global distribution and burden of dengue

Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus

Dengue: A minireview

Antibody-dependent enhancement of severe dengue disease in humans

Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion

Recognition determinants of broadly neutralizing human antibodies against dengue viruses

World Health Organization. Global strategy for dengue prevention and control

Effect of dengue serostatus on dengue vaccine safety and efficacy

Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice

An envelope-modified tetravalent dengue virus-like-particle vaccine has implications for flavivirus vaccine design

Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris

Dengue envelope-based 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice

A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2

Production of dengue virus-like particles serotype-3 in silkworm larvae and their ability to elicit a humoral immune response in mice

Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus

Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to vero cells

Studies on the nature of dengue viruses. I. Correlation of particle density, infectivity, and RNA content of type 2 virus

Physical and biological properties of dengue-2 virus and associated antigens

Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope

Development of a Japanese encephalitis virus-like particle vaccine in silkworms using codon-optimised prM and envelope genes

Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature

Pichia pastoris-expressed bivalent virus-like particulate vaccine induces domain III-focused bivalent neutralizing antibodies without antibody-dependent enhancement in vivo

Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography

Atomic-level functional model of dengue virus Envelope protein infectivity

High-throughput neutralization assay for multiple flaviviruses based on single-round infectious particles using dengue virus type 1 reporter replicon

SWISS-MODEL: Homology modelling of protein structures and complexes

UCSF Chimera-A visualization system for exploratory research and analysis

Agglutination of human polyomaviruses by using a tetravalent glycocluster as a cross-linker

R: A language and environment for statistical computing

T.S. and R.S. conceived and designed the study. T.I., M.I., M.M., K.N., Y.T., I.O., T.L. and T.S. performed experiments. T.I., M.I., M.M., R.S. and T.S. analyzed and interpreted the data. T.I. and T.S. wrote the manuscript. All authors reviewed the manuscript.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-97038-4.Correspondence and requests for materials should be addressed to T.S.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.